A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression (TMS-BD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00699218|
Recruitment Status : Completed
First Posted : June 17, 2008
Results First Posted : July 23, 2018
Last Update Posted : July 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Mood Disorder Bipolar Disorder Major Depression Depression||Device: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Device Feasibility|
|Official Title:||A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment of Bipolar Depression|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||April 2010|
Experimental: rTMS treatment
Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
Device: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.
High frequency repetitive TMS given daily on weekdays for 3 weeks
Other Name: Repetitive Transcranial Magnetic Stimulation (rTMS)
- Hamilton Rating Scale for Depression (HAM-D) [ Time Frame: 5 weeks ]Scored Questionnaire 0-52, A score of 0-7 is considered to be normal. Scores of 20 or higher indicate moderate, severe, or very severe depression. The higher score means more severe depression.
- Inventory of Depressive Symptomatology [ Time Frame: 5 weeks ]Self reported depression scale range 0-84. Questionnaire administered at 1,2, and 3 weeks (end of treatment). We also did a 5 week follow-up. The higher scores indicate greater or more severe depression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00699218
|United States, California|
|Center for Mind and Brain|
|Davis, California, United States, 95618|
|Principal Investigator:||Guohua Xia, M.D., Ph.D.||Department of Psychiatry and Behavioral Sciences, UC Davis|